Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vecuronium Bromide

FDA-approved product (injectable, injection), marketed as Norcuron, Vecuronium Bromide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vecuronium Bromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Vecuronium Bromide. Its therapeutic class is shown instead.

WHO therapeutic group
Other quaternary ammonium compounds
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vecuronium Bromide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-3.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vecuronium Bromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Application of THRIVE in Burn Children With Suspected Difficult Airway

    NCT06459076 · start 2024-07-01

    Registered record
    Registry ID
    NCT06459076
    Conditions
    Intubation; Difficult or Failed
    Interventions
    Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-07-01
    Completion
    2026-05
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntubation; Difficult or Failed
    InterventionTransnasal humidified rapid-insufflation ventilatory exchange (THRIVE)
    PhaseNot applicable
    Registry statusUnknown

  • Effect of Opioid-Free vs Opioid-Based Anesthesia on Postoperative Pain and Emergence Agitation in Children Undergoing Cleft Surgery

    NCT07557576 · start 2024-05-16

    Registered record
    Registry ID
    NCT07557576
    Conditions
    Cleft Lip Palate; Orofacial Cleft; Agitation, Emergence; Analgesia Assessment; Analgesia; Pediatric
    Interventions
    Ketamine (1 mg/kg); Dexmedetomidine (1-0,8-0,6-0,4 mcg/kg/h); Fentanyl 5 mcg/kg; Propofol (IV) 3-4 mg/kg; Sevoflurane (Volatile Anesthetic); Nitrous Oxide/Oxygen; Vecuronium (0.1 mg/kg)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-05-16
    Completion
    2026-09-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCleft Lip Palate; Orofacial Cleft; Agitation, Emergence; Analgesia Assessment +2 more
    InterventionKetamine (1 mg/kg); Dexmedetomidine (1-0,8-0,6-0,4 mcg/kg/h); Fentanyl 5 mcg/kg; Propofol (IV) 3-4 mg/kg +3 more
    PhaseNot applicable
    Registry statusRecruiting

  • Effect of Desflurane v/s Propofol on the Optic Nerve Sheath Diameter

    NCT07359508 · start 2024-01-10

    Registered record
    Registry ID
    NCT07359508
    Conditions
    Propofol Target-controlled Infusion; Desflurane; Optic Nerve Sheath Diameter
    Interventions
    Desflurane; Propofol (Group P)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-01-10
    Completion
    2025-07-15
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPropofol Target-controlled Infusion; Desflurane; Optic Nerve Sheath Diameter
    InterventionDesflurane; Propofol (Group P)
    PhasePhase 4
    Registry statusCompleted

  • Continuous Versus 1-min Oscillometric Arterial BP Monitoring

    NCT05792436 · start 2023-04-27

    Registered record
    Registry ID
    NCT05792436
    Conditions
    Anesthesia, General
    Interventions
    1-min interval oscillometric method; arterial catheterization method
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-04-27
    Completion
    2025-08-21
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnesthesia, General
    Intervention1-min interval oscillometric method; arterial catheterization method
    PhaseNot applicable
    Registry statusCompleted

  • An Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety

    NCT05788718 · start 2023-04-11

    Registered record
    Registry ID
    NCT05788718
    Conditions
    Postoperative Complications; Neuromuscular Blockade; Anesthesia
    Interventions
    Sugammadex
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-04-11
    Completion
    2025-05-08
    Enrolment
    6,458

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Complications; Neuromuscular Blockade; Anesthesia
    InterventionSugammadex
    PhaseNot recorded
    Registry statusCompleted

  • Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

    NCT05658692 · start 2022-10-01

    Registered record
    Registry ID
    NCT05658692
    Conditions
    Acute Respiratory Distress Syndrome
    Interventions
    protective ventilation; prone position ventilation; glucocorticoid therapy; restrictive fluid resuscitation; Thymosin Alpha; Muscle relaxant therapy; Integrated Chinese and Western Medicine Treatment; statin therapy; anti-infective treatment; Extracorporeal Membrane Oxygenation（ECMO）; stem cell therapy; Sedative analgesia/muscle relaxant therapy; inotropes therapy; Vasoactive drug therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-10-01
    Completion
    2023-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Distress Syndrome
    Interventionprotective ventilation; prone position ventilation; glucocorticoid therapy; restrictive fluid resuscitation +10 more
    PhasePhase 4
    Registry statusUnknown

  • Pharmacokinetics and Pharmacodynamics of Sugammadex Dosed by Corrected Body Weight for Reversal of Vecuronium in Obese Patients

    NCT05328778 · start 2022-04-14

    Registered record
    Registry ID
    NCT05328778
    Conditions
    Pharmacokinetics
    Interventions
    Sugammadex
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-04-14
    Completion
    2026-04-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionSugammadex
    PhasePhase 4
    Registry statusCompleted

  • GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries

    NCT05444751 · start 2022-03-22

    Registered record
    Registry ID
    NCT05444751
    Conditions
    Lumbar Disc Herniation; Lumbar Disc Disease; Lumbar Radiculopathy
    Interventions
    General anesthetic; SA + ESP
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2022-03-22
    Completion
    2026-09
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLumbar Disc Herniation; Lumbar Disc Disease; Lumbar Radiculopathy
    InterventionGeneral anesthetic; SA + ESP
    PhasePhase 3
    Registry statusEnrolling by invitation

  • Sugammadex Titration in Cardiac Surgery Patients

    NCT05246397 · start 2022-02-01

    Registered record
    Registry ID
    NCT05246397
    Conditions
    Coronary Artery Disease; Valvular Heart Disease; Aorta Disease; Heart Failure
    Interventions
    Sugammadex administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-02-01
    Completion
    2022-11-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Valvular Heart Disease; Aorta Disease; Heart Failure
    InterventionSugammadex administration
    PhasePhase 4
    Registry statusCompleted

  • Trial of Therapeutic Hypothermia in Patients With ARDS

    NCT04545424 · start 2021-06-29

    Registered record
    Registry ID
    NCT04545424
    Conditions
    Respiratory Distress Syndrome, Adult
    Interventions
    Hypothermia; Neuromuscular Blocking Agents; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-06-29
    Completion
    2026-09-30
    Enrolment
    340

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Distress Syndrome, Adult
    InterventionHypothermia; Neuromuscular Blocking Agents; Standard of care
    PhasePhase 2
    Registry statusActive not recruiting

  • Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy

    NCT05468671 · start 2021-01-04

    Registered record
    Registry ID
    NCT05468671
    Conditions
    Endobronchial Metastases; Bronchoesophageal Fistula; General Anesthetic Drug Adverse Reaction
    Interventions
    Remimazolam; Propofol; Rocuronium; Remifentanil; oxycodone; Sugammadex Sodium; Flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-01-04
    Completion
    2022-09-08
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndobronchial Metastases; Bronchoesophageal Fistula; General Anesthetic Drug Adverse Reaction
    InterventionRemimazolam; Propofol; Rocuronium; Remifentanil +3 more
    PhasePhase 4
    Registry statusCompleted

  • The Effects of Method of Anaesthesia on the Safety and Effectiveness of Radical Retropubic Prostatectomy

    NCT05566405 · start 2020-07-27

    Registered record
    Registry ID
    NCT05566405
    Conditions
    Prostatic Neoplasm
    Interventions
    General Anaesthesia; Combined (Epidural and Spinal) Anaesthesia; Open Retropubic Radical Prostatectomy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-07-27
    Completion
    2022-09-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasm
    InterventionGeneral Anaesthesia; Combined (Epidural and Spinal) Anaesthesia; Open Retropubic Radical Prostatectomy
    PhaseNot applicable
    Registry statusCompleted

  • LPB Combined with QLB Using Single-needle Technique (LPQLB-SNT) for Hip Arthroplasty

    NCT04266236 · start 2020-07-09

    Registered record
    Registry ID
    NCT04266236
    Conditions
    Hip Osteoarthritis; Anesthesia, Local; Hip Fractures; Osteonecrosis of Femoral Head
    Interventions
    L3 LPB; L4 LPB; T12 block; L3 QLB; 0.375%ropivacaine 25 ml (Raropin); 0.375%ropivacaine 40 ml (Raropin); General anesthesia with tracheal intubation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-07-09
    Completion
    2024-06-30
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHip Osteoarthritis; Anesthesia, Local; Hip Fractures; Osteonecrosis of Femoral Head
    InterventionL3 LPB; L4 LPB; T12 block; L3 QLB +3 more
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

    NCT03909165 · start 2019-07-23

    Registered record
    Registry ID
    NCT03909165
    Conditions
    Neuromuscular Blockade
    Interventions
    Sugammadex 2 mg/kg; Sugammadex 4 mg/kg; Neostigmine + Glycopyrrolate; Neostigmine + Atropine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-07-23
    Completion
    2023-09-21
    Enrolment
    145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromuscular Blockade
    InterventionSugammadex 2 mg/kg; Sugammadex 4 mg/kg; Neostigmine + Glycopyrrolate; Neostigmine + Atropine
    PhasePhase 4
    Registry statusCompleted

  • Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine

    NCT03656614 · start 2018-07-26

    Registered record
    Registry ID
    NCT03656614
    Conditions
    Neuromuscular Blockade
    Interventions
    Sugammadex; Neostigmine; Saline 0.9%
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-07-26
    Completion
    2019-06-30
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromuscular Blockade
    InterventionSugammadex; Neostigmine; Saline 0.9%
    PhaseNot recorded
    Registry statusCompleted